Post cardiac injury syndrome: Difference between revisions
Jump to navigation
Jump to search
m (Robot: Changing Category:Disease state to Category:Disease) |
No edit summary |
||
| Line 9: | Line 9: | ||
#[[Post myocardial infarction syndrome]] ([[PMIS]]) or [[Dressler's syndrome]] and | #[[Post myocardial infarction syndrome]] ([[PMIS]]) or [[Dressler's syndrome]] and | ||
#[[Postpericardiotomy syndrome]] ([[PCS]]) | #[[Postpericardiotomy syndrome]] ([[PCS]]) | ||
==Historical Perspective== | |||
*[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event]. | |||
*In [year], [gene] mutations were first identified in the pathogenesis of [disease name]. | |||
*In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name]. | |||
==Classification== | |||
*[Disease name] may be classified according to [classification method] into [number] subtypes/groups: | |||
:*[group1] | |||
:*[group2] | |||
:*[group3] | |||
*Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3]. | |||
==Pathophysiology== | ==Pathophysiology== | ||
Both syndromes represent the delayed occurrence of [[pericarditis]]. [[Post-myocardial infarction syndrome]] is obviously due to [[myocardial infarction]] and [[postpericardiotomy syndrome]] is due to the myocardial injury that occurs during cardiac surgery. Both syndromes are thought to represent an autoimmune process with the development of anti-heart antibodies. | Both syndromes represent the delayed occurrence of [[pericarditis]]. [[Post-myocardial infarction syndrome]] is obviously due to [[myocardial infarction]] and [[postpericardiotomy syndrome]] is due to the myocardial injury that occurs during cardiac surgery. Both syndromes are thought to represent an autoimmune process with the development of anti-heart antibodies. | ||
==Clinical Features== | |||
==Differentiating [disease name] from other Diseases== | |||
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as: | |||
:*[Differential dx1] | |||
:*[Differential dx2] | |||
:*[Differential dx3] | |||
==Epidemiology and Demographics== | |||
* The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide. | |||
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location]. | |||
===Age=== | |||
*Patients of all age groups may develop [disease name]. | |||
*[Disease name] is more commonly observed among patients aged [age range] years old. | |||
*[Disease name] is more commonly observed among [elderly patients/young patients/children]. | |||
===Gender=== | |||
*[Disease name] affects men and women equally. | |||
*[Gender 1] are more commonly affected with [disease name] than [gender 2]. | |||
* The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1. | |||
===Race=== | |||
*There is no racial predilection for [disease name]. | |||
*[Disease name] usually affects individuals of the [race 1] race. | |||
*[Race 2] individuals are less likely to develop [disease name]. | |||
==Risk Factors== | |||
*Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4]. | |||
== Natural History, Complications and Prognosis== | == Natural History, Complications and Prognosis== | ||
| Line 17: | Line 60: | ||
==Diagnosis== | ==Diagnosis== | ||
===Diagnostic Criteria=== | |||
*The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: | |||
:*[criterion 1] | |||
:*[criterion 2] | |||
:*[criterion 3] | |||
:*[criterion 4] | |||
===Symptoms=== | ===Symptoms=== | ||
Both syndromes share common symptoms which include [[fever]] and [[pleuritic]] pain. | Both syndromes share common symptoms which include [[fever]] and [[pleuritic]] pain. | ||
| Line 43: | Line 92: | ||
#Adversely impact left ventricular remodeling. | #Adversely impact left ventricular remodeling. | ||
#Block the effectiveness of [[aspirin]] | #Block the effectiveness of [[aspirin]] | ||
== Treatment == | |||
=== Medical Therapy === | |||
*There is no treatment for [disease name]; the mainstay of therapy is supportive care. | |||
*The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2]. | |||
*[Medical therapy 1] acts by [mechanism of action 1]. | |||
*Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration]. | |||
=== Surgery === | |||
*Surgery is the mainstay of therapy for [disease name]. | |||
*[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name]. | |||
*[Surgical procedure] can only be performed for patients with [disease stage] [disease name]. | |||
=== Prevention === | |||
*There are no primary preventive measures available for [disease name]. | |||
*Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3]. | |||
*Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3]. | |||
===ACC/AHA Treatment Guidelines (DO NOT EDIT)<ref name="pmid15339869">{{cite journal |author=Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK |title=ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) |journal=Circulation |volume=110 |issue=9 |pages=e82–292 |year=2004 |month=August |pmid=15339869 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=15339869}}</ref>=== | ===ACC/AHA Treatment Guidelines (DO NOT EDIT)<ref name="pmid15339869">{{cite journal |author=Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK |title=ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) |journal=Circulation |volume=110 |issue=9 |pages=e82–292 |year=2004 |month=August |pmid=15339869 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=15339869}}</ref>=== | ||
Revision as of 14:41, 23 April 2020
|
Pericarditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Surgery |
|
Case Studies |
|
Post cardiac injury syndrome On the Web |
|
American Roentgen Ray Society Images of Post cardiac injury syndrome |
|
Risk calculators and risk factors for Post cardiac injury syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: PCIS
Overview
Post cardiac injury syndrome (PCIS) encompasses two causes of pericarditis:
- Post myocardial infarction syndrome (PMIS) or Dressler's syndrome and
- Postpericardiotomy syndrome (PCS)
Historical Perspective
- [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
- In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
- In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
Classification
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
- Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
Pathophysiology
Both syndromes represent the delayed occurrence of pericarditis. Post-myocardial infarction syndrome is obviously due to myocardial infarction and postpericardiotomy syndrome is due to the myocardial injury that occurs during cardiac surgery. Both syndromes are thought to represent an autoimmune process with the development of anti-heart antibodies.
Clinical Features
Differentiating [disease name] from other Diseases
- [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
- In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
Age
- Patients of all age groups may develop [disease name].
- [Disease name] is more commonly observed among patients aged [age range] years old.
- [Disease name] is more commonly observed among [elderly patients/young patients/children].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected with [disease name] than [gender 2].
- The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
Race
- There is no racial predilection for [disease name].
- [Disease name] usually affects individuals of the [race 1] race.
- [Race 2] individuals are less likely to develop [disease name].
Risk Factors
- Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Natural History, Complications and Prognosis
Most often the course of PCIS is benign. Rare complications include development of cardiac tamponade, pericardial constriction, and saphenous vein graft occlusion.
Diagnosis
Diagnostic Criteria
- The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
Symptoms
Both syndromes share common symptoms which include fever and pleuritic pain.
Physical Examination
The following findings may be present:
Cardiovascular
Lungs
Laboratory Studies
The following lab abnormalities may be present:
- An elevated erythrocyte sedimentation rate.
- A leukocytosis.
Chest x-ray
A pleural effusion with or without pulmonary infiltrates may be present.
Treatment
Dressler's syndrome is typically treated with high dose (up to 650 mg PO q 4 to 6 hours) enteric-coated aspirin. Acetominophen can be added for pain management as this does not affect the coagulation system. Anticoagulants should be discontinued if the patient develops a pericardial effusion.
NSAIDs such as ibuprofen should be avoided in the peri-infarct period as they:
- Increase the risk of reinfarction
- Adversely impact left ventricular remodeling.
- Block the effectiveness of aspirin
Treatment
Medical Therapy
- There is no treatment for [disease name]; the mainstay of therapy is supportive care.
- The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action 1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
- Surgery is the mainstay of therapy for [disease name].
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
- [Surgical procedure] can only be performed for patients with [disease stage] [disease name].
Prevention
- There are no primary preventive measures available for [disease name].
- Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].
ACC/AHA Treatment Guidelines (DO NOT EDIT)[1]
| “ |
Class I1. Aspirin is recommended for treatment of pericarditis after STEMI. Doses as high as 650 mg orally (entericcoated) every 4 to 6 hours may be needed. (Level of Evidence: B) 2. Anticoagulation should be immediately discontinued if pericardial effusion develops or increases. (Level of Evidence: C) Class IIa1. For episodes of pericarditis after STEMI that are not adequately controlled with aspirin, it is reasonable to administer 1 or more of the following:
Class IIb1. Corticosteroids might be considered only as a last resort in patients with pericarditis refractory to aspirin or NSAIDs. Although corticosteroids are effective for pain relief, their use is associated with an increased risk of scar thinning and myocardial rupture. (Level of Evidence: C) 2. Nonsteroidal anti-inflammatory drugs may be considered for pain relief; however, they should not be used for extended periods because of their effect on platelet function, an increased risk of myocardial scar thinning, and infarct expansion. (Level of Evidence: B) Class III1. Ibuprofen should not be used for pain relief because it blocks the antiplatelet effect of aspirin and it can cause myocardial scar thinning and infarct expansion. (Level of Evidence: B) |
” |
Sources
- The 2004 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction [1]
- The 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction [2]
References
- ↑ 1.0 1.1 Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK (2004). "ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)". Circulation. 110 (9): e82–292. PMID 15339869. Unknown parameter
|month=ignored (help) - ↑ Antman EM, Hand M, Armstrong PW; et al. (2008). "2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee". Circulation. 117 (2): 296–329. doi:10.1161/CIRCULATIONAHA.107.188209. PMID 18071078. Unknown parameter
|month=ignored (help)